U.S., Nov. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07243340) titled 'A Phase I/IIa Study of C5252 in Patients With Intracranial Tumor' on Nov. 16.
Brief Summary: This study includes phase I dose escalation part and phase IIa dose expansion part. The goal of this clinical trial is to learn if C5252 treatment is safe and well tolerated in patients with intracranial tumor and to learn preliminary efficacy of C5252. In this study, participants will be given single or multiple doses of C5252 according to protocol followed by toxicity observation, safety follow-up and long-term follow-up.
Study Start Date: Dec. 15
Study Type: INTERVENTIONAL
Condition:
Glioma, Malignant
Intervention:
BIOLOGICAL: Herpe...